Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of action
Mark Austin(John Innes Centre), Maria Groves(AstraZeneca (United Kingdom)), Lesley Jenkinson(AstraZeneca (United Kingdom)), Yoko Shibata(Fukushima Medical University), Stephanie Ryman(AstraZeneca (United Kingdom)), Jessica Whitehouse(AstraZeneca (United Kingdom)), Mark D. Carr(University of Leicester), Sarah V. Holt(Pharma Nord (United Kingdom)), Stuart W. Haynes(AstraZeneca (United Kingdom)), Robert W. Wilkinson(Immunocore (United Kingdom)), Andreas V. Hadjinicolaou(University of Oxford), Tristan J. Vaughan(AstraZeneca (United Kingdom)), Michelle Barnard(North-West University), C. Seewooruthun(University of Leicester), Louise H. Slater(AstraZeneca (United Kingdom)), Teresa Kaserer(Universität Innsbruck), A. Addyman(AstraZeneca (United Kingdom)), Denice T. Y. Chan(AstraZeneca (United Kingdom)), Uzi Gileadi(John Radcliffe Hospital), Nadia Luheshi(AstraZeneca (United Kingdom)), Ellen Gowans(AstraZeneca (United Kingdom)), Sebastian Fiedler(AstraZeneca (United Kingdom)), Agata Diamandakis(AstraZeneca (United Kingdom)), Vincenzo Cerundolo(John Radcliffe Hospital), Pooja Sharma(AstraZeneca (United Kingdom)), D. Burschowsky(University of Leicester)
Cited by 10
Related Papers
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
|Nature Medicine|2002|1.6k
Classification of current anticancer immunotherapies
|Oncotarget|2014|469
Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
|Proceedings of the National Academy of Sciences|2000|398
The crystal structure of human CD1d with and without α-galactosylceramide
|Nature Immunology|2005|389